Recent Finacing
Recent Raise
Kither Biotech, a University of Turin spin-off, develops inhaled peptide KIT-2014 to modulate intracellular cAMP for cystic fibrosis and a PI3K inhibitor prodrug for idiopathic pulmonary fibrosis.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Kither Biotech.
